Literature DB >> 15615519

Stereochemical studies of the monocyclic agouti-related protein (103-122) Arg-Phe-Phe residues: conversion of a melanocortin-4 receptor antagonist into an agonist and results in the discovery of a potent and selective melanocortin-1 agonist.

Christine G Joseph1, Xiang S Wang, Joseph W Scott, Rayna M Bauzo, Zhimin Xiang, Nigel G Richards, Carrie Haskell-Luevano.   

Abstract

The agouti-related protein (AGRP) is an endogenous antagonist of the centrally expressed melanocortin receptors. The melanocortin-4 receptor (MC4R) is involved in energy homeostasis, food intake, sexual function, and obesity. The endogenous hAGRP protein is 132 amino acids in length, possesses five disulfide bridges at the C-terminus of the molecule, and is expressed in the hypothalamus of the brain. We have previously reported that a monocyclic hAGRP(103-122) peptide is an antagonist at the melanocortin receptors expressed in the brain. Stereochemical inversion from the endogenous l- to d-isomers of single or multiple amino acid modifications in this monocyclic truncated hAGRP sequence resulted in molecules that are converted from melanocortin receptor antagonists into melanocortin receptor agonists. The Asp-Pro-Ala-Ala-Thr-Ala-Tyr-cyclo[Cys-Arg-DPhe-DPhe-Asn-Ala-Phe-Cys]-Tyr-Ala-Arg-Lys-Leu peptide resulted in a 60 nM melanocortin-1 receptor agonist that is 100-fold selective versus the mMC4R, 1000-fold selective versus the mMC3R, and ca. 180-fold selective versus the mMC5R. In attempts to identify putative ligand-receptor interactions that may be participating in the agonist induced stimulation of the MC4R, selected ligands were docked into a homology molecular model of the mMC4R. These modeling studies have putatively identified hAGRP ligand DArg111-mMC4RAsn115 (TM3) and the hAGRP DPhe113-mMC4RPhe176 (TM4) interactions as important for agonist activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615519     DOI: 10.1021/jm0492756

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Arg-Phe-Phe d-Amino Acid Stereochemistry Scan in the Macrocyclic Agouti-Related Protein Antagonist Scaffold c[Pro-Arg-Phe-Phe-Xxx-Ala-Phe-DPro] Results in Unanticipated Melanocortin-1 Receptor Agonist Profiles.

Authors:  Mark D Ericson; Zoe M Koerperich; Katie T Freeman; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-07-20       Impact factor: 4.418

2.  Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AgRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists.

Authors:  Zoe M Koerperich; Mark D Ericson; Katie T Freeman; Robert C Speth; Irina D Pogozheva; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2020-01-06       Impact factor: 7.446

3.  Discovery of a β-Hairpin Octapeptide, c[Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], Mimetic of Agouti-Related Protein(87-132) [AGRP(87-132)] with Equipotent Mouse Melanocortin-4 Receptor (mMC4R) Antagonist Pharmacology.

Authors:  Mark D Ericson; Andrzej Wilczynski; Nicholas B Sorensen; Zhimin Xiang; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2015-04-21       Impact factor: 7.446

4.  Discovery of Mixed Pharmacology Melanocortin-3 Agonists and Melanocortin-4 Receptor Tetrapeptide Antagonist Compounds (TACOs) Based on the Sequence Ac-Xaa1-Arg-(pI)DPhe-Xaa4-NH2.

Authors:  Skye R Doering; Katie T Freeman; Sathya M Schnell; Erica M Haslach; Marvin Dirain; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Robert C Speth; Richard A Houghten; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-05-15       Impact factor: 7.446

5.  Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments.

Authors:  Stéphanie M Guéret; Sasikala Thavam; Rodrigo J Carbajo; Marco Potowski; Niklas Larsson; Göran Dahl; Anita Dellsén; Tom N Grossmann; Alleyn T Plowright; Eric Valeur; Malin Lemurell; Herbert Waldmann
Journal:  J Am Chem Soc       Date:  2020-03-02       Impact factor: 15.419

6.  Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.

Authors:  Zhan-Guo Gao; Kai Ye; Anikó Göblyös; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  BMC Pharmacol       Date:  2008-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.